[go: up one dir, main page]

WO2000012454A1 - Nouveaux lipides cationiques - Google Patents

Nouveaux lipides cationiques Download PDF

Info

Publication number
WO2000012454A1
WO2000012454A1 PCT/US1999/019629 US9919629W WO0012454A1 WO 2000012454 A1 WO2000012454 A1 WO 2000012454A1 US 9919629 W US9919629 W US 9919629W WO 0012454 A1 WO0012454 A1 WO 0012454A1
Authority
WO
WIPO (PCT)
Prior art keywords
compound
cells
composition
lipids
transfection
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US1999/019629
Other languages
English (en)
Other versions
WO2000012454A9 (fr
Inventor
Alberto Haces
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to AU55881/99A priority Critical patent/AU5588199A/en
Publication of WO2000012454A1 publication Critical patent/WO2000012454A1/fr
Publication of WO2000012454A9 publication Critical patent/WO2000012454A9/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/084—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/088—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/02—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C217/04—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C217/06—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted
    • C07C217/08—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted the oxygen atom of the etherified hydroxy group being further bound to an acyclic carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C219/00—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton
    • C07C219/02—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C219/04—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C219/06—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having the hydroxy groups esterified by carboxylic acids having the esterifying carboxyl groups bound to hydrogen atoms or to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C229/06—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton
    • C07C229/10—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings
    • C07C229/16—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings to carbon atoms of hydrocarbon radicals substituted by amino or carboxyl groups, e.g. ethylenediamine-tetra-acetic acid, iminodiacetic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/34—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups
    • C07C233/35—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
    • C07C233/36—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of an acyclic saturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C237/10—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atom of at least one of the carboxamide groups bound to an acyclic carbon atom of a hydrocarbon radical substituted by nitrogen atoms not being part of nitro or nitroso groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
    • C07C279/04—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton
    • C07C279/08—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton being further substituted by singly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
    • C07C279/04—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton
    • C07C279/12—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton being further substituted by nitrogen atoms not being part of nitro or nitroso groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
    • C07F9/10—Phosphatides, e.g. lecithin

Definitions

  • This invention relates to polycationic lipids useful for the delivery (transfection) of nucleic acids (DNA,RNA) and other negatively charged or neutral molecules into living cells, either in vivo or in vitro.
  • Liposome aggregates made with polycationic lipids are useful structures capable of complexing with negatively charged macromolecules such as DNA or RNA. These complexes can be taken up by living cells and then, once inside the cytosol, through an unknown mechanism, they are presumed to migrate into the cell nucleus. In the nucleus, there are enzymes capable of "reading” and “expressing” the message coded by the nucleic acids so delivered and produce new proteins, which were not being produced by the cell before the transfection of the foreign nucleic acid. When cells so transfected divide and their daughter cells still have the capability to produce the proteins encoded by the initially transfected DNA, the transfection is said to be stable.
  • the new DNA has stably integrated into the cell nucleus changing the cell's genetic make-up.
  • the parent cells can produce the protein encoded by the transfected DNA, but their daughter cells are not capable of expressing that tranfected DNA, the transfection is said to be transient.
  • RNA transfection is always transient. Stable transfection of human or animal cells is the basis of so called gene therapy, since cells which are deficient in a crucial protein for the organism's survival could in principle be repaired by stably transfecting the DNA needed to produce the absent protein.
  • Another type of potential use of DNA/RNA transfection for therapy is antisense therapy.
  • nucleic acid capable of adhering (hybridizing) to defective DNA (or RNA) which is being expressed by the cells to produce an undesired protein, such as an oncoprotein (cancer causing protein)
  • an undesired protein such as an oncoprotein (cancer causing protein)
  • This method of therapy does not change the genetic make-up of the cell, but blocks the effect of the genetic disorder already present in the cell's genome.
  • polycationic lipids for use in human therapy, there is already a well established market for these types of chemicals in the research products field. They are currently being used by researchers to deliver nucleic acids and proteins into cells in order to study how the expression of different genes affect cell growth and function.
  • ex vivo and in vivo transfection There are two possible ways to deliver DNA into cells for gene therapy : ex vivo and in vivo transfection.
  • ex vivo modality cells from a patient are removed from the body, cultured and transfected in vitro. Then, the cells are returned into the patient where the beneficial DNA message is hopefully expressed.
  • the DNA is delivered directly into the patient, which makes this procedure simpler and less expensive.
  • the only effective way to deliver DNA in vivo is by using a virus which naturally infects cells of a specific organ (targets that organ) within the body, and whose genetic make up has been modified by adding the DNA beneficial to the patient.
  • the virus can incorporate the new DNA in the genome of the cell (stable transfection) and the parent cell and its daughters can express the beneficial protein.
  • the pathological component of the virus has been deleted before the patient is exposed to such a virus and only the targeting component left intact. Virus can do this process sometimes with nearly 100% efficiency.
  • there are risks associated with their use since they can produce immunological reactions which may be fatal to the patient; the DNA incorporation in the cell's genome is random, therefore it might disrupt needed genes or activate oncogenes; they are also difficult to mass produce, and so forth.
  • Liposomes or lipid aggregates do not have the side effects of viruses, but are not as efficient as viruses are. There is a constant need to develop newer lipids that can approach the efficiency of viruses without their undesirable side effects (E. Marshall, Science 269,1050 (1995)) . There are several lipids for nucleic acids transfection already in the market. The most relevant of these lipids are: (a) DOTMA (N-[l-(2,3-dioleoyloxy)propyl]- N,N,N - trimethylammonium chloride, U.S. Pat. No. 4,897,355 to D.
  • DOTMA N-[l-(2,3-dioleoyloxy)propyl]- N,N,N - trimethylammonium chloride
  • DOGS is sold under the trade name TransfectamTM by the Promega Corp. Madison, Wl );
  • DDAB Dimethyloctadecylammoniumbromide, U.S. Pat. No.
  • DOGS dioleolylphosphatidylethanolamine
  • DOPE dioleolylphosphatidylethanolamine
  • lipids are useful as transfection reagents for nucleic acids, oligonucleotides, mononucleotides, polypeptides, and proteins.
  • some of these lipids are also useful as more effective detergents for cleaning and as vehicles in the cosmetic field.
  • novel oxo and sulfinyl backbone substituted polycationic lipids with ammonium, guanidinium and amidinium positively charged moieties as anchoring groups having Formula I as shown below and in WO 97/42819 (International Application No. PCT/US97/09093), the contents of which is fully incorporated herein by reference.
  • the present invention also encompasses a series of novel phosphatidyl and glyceryl guanidinium cationic lipids having the formula 2 shown below and in Figure 8.
  • the backbone of the substituted polycationic lipis is comprised of a polyether in accordance with Formula 3 as shown in Figure 9:
  • Figure 1 is a graphic representation of Scheme I for the preparation of polycationic lipids of the present invention.
  • Figure 2 is a graphic representation of Scheme LI for the preparation of polycationic lipids of the present invention.
  • Figure 3 is a graphic representation of Scheme -31 for the preparation of polycationic lipids of the present invention.
  • Figure 4 is a graphic representation of Scheme IV for the preparation of polycationic lipids of the present invention.
  • Figure 5 is a graphic representation of Scheme V for the preparation of polycationic lipids of the present invention.
  • Figure 6 is a graphic representation of Scheme VI for the preparation of polycationic lipids of the present invention.
  • Figure 7 is a graphic representation of Formula 1, which represents a series of polycationic lipids of the present invention.
  • Figure 8 is a graphic representation of Formula 2, which represents a second series of polycationic lipids of the present invention.
  • Figure 9 is a graphic representation of Formula 3, which represents a third series of polycationic lipids of the present invention.
  • Figure 10 is a graphic representation of Formula 4, which represents a fourth series of polycationic lipids of the present invention.
  • Figure 11 is a graphic representation of compound 13a of the present invention.
  • Figure 12 is a graphic representation of compound 13d of the present invention.
  • Figure 13 is a graphic representation of compound 5a of the present invention.
  • Figure 14 is a graphic representation of compound 13b of the present invention.
  • Figure 15 is a graphic representation of compound 6d of the present invention.
  • Figure 16 is a graphic representation of compound 15 of the present invention.
  • the compounds of the present invention can be used alone or in mixtures with other compounds
  • liposome forming compounds (co-lipids) to prepare lipid aggregates which are useful to deliver
  • Colipids are compounds capable of producing stable liposomes, alone, or in combination with other lipid components. Such colipids are preferably neutral, although they can alternatively be positively or negatively charged. Some colipids are
  • Such examples include phospholipid-related materials, such as lecithin, phosphatidylethanolamine, lysolecithin, lysophosphatidylethanolamine, phosphatidylserine, phosphatidylinositol, sphinogomyelin, cephalin, cardiolipin, phosphatidic
  • POPE dioleoylphosphatidylethanolamine 4-(N-maleimidomethyl)cyclohexane-l- carboxylate
  • DOPE-mal dioleoylphosphatidylethanolamine 4-(N-maleimidomethyl)cyclohexane-l- carboxylate
  • Additional non-phosphorous containing lipids are, e.g.,
  • the lipids depicted in Formula I have a hydrocarbon backbone substituted with
  • heteroatoms which are sterically smaller, but equally or more flexible as the methylene group that they replace. This feature makes these new lipids fit more closely to the macromolecule to be delivered to the cells. This closer fit combined with the polycationic nature of the
  • heteroatoms are hydrophilic; thus,
  • hydrophilic backbone being linear allows for proper
  • one of the preferred embodiments is compound 5a, as shown in Figure 13, which has four hydrophobic tails and two positive charges (two tails per charge).
  • Figures 11 and 14 have fewer hydrophobic tails and a more hydrophobic backbone (no heteroatom substitution, but less hydrophobic overall). However, these compounds have moieties which mimic small natural biological effectors such as the neurotransmitters gamma
  • GAB A amino butyric acid
  • acetylcholine etc.
  • guanidino moiety can also be used to target
  • guanidinium or amidinium functionality is used as the positively charged anchoring group
  • This compound has the ability to form liposomes without the need of co-adjuvants such as DOPE or DOPC. Thus, it can be used to form liposomes with other cationic lipid compounds.
  • LAH lithium aluminum hydride
  • amidine(6e) Alternatively, the latter amidine derivatives can be
  • isothiouronium hydroiodide (S-methyl thiourea) in tetrahydrofurane in the presence of triethylamine. Additionally, this guanidinium derivative can be alkylated with, for example,
  • Diamide-dinitrile (8) was then easily obtained by treatment of compound (7) with an acyl halide such as palmitoyl chloride in methylene
  • Guanidinium compound (10) can be
  • Example 2 Synthesis of bis (mono and dialkyl iglycolamides(3a-d), general procedure.
  • Example 4 Synthesis of N,N.N,N'.N'.N' - dioctadecylmethyl-2,2'-oxybisethylammonium iodide.(5a).
  • N,N,N',N'-dioctadecyl-2,2'-oxy bis ethylamine (19mg, 0.017mmol) was dissolved in iodomethane (1ml) inside a capped thick-wall test tube, and the resulting solution heated for
  • Example 6 Synthesis of N.N.N.N'.N'.N'-cyanoethyloctadecylmethyl-2.2'-oxybis ethyl ammonium iodide (5e).
  • Example 7 Synthesis of N,N,N,N',N',N'- acetoxyethyldioctadecyl-2.2'-oxybis ethyl ammonium iodide(5f).
  • 1,4-diaminobutane (2g, 22 mmol) was cooled to 0C (ice bath) and to this solid was
  • Example 15 Synthesis of N,N',N",N"'-tetrapalmyitetraacetoxyethy,spermine iodide salt(13a): A solution of tetrapalmylspermine (Haces et al.,PCT Int. Pub. No WO/95/17373), 130mg, mmol) in neat ethyl iodoacetate (1.5ml) was heated to 75°C for 18h. The reaction was
  • Lipids were formulated by mixing appropriate molar amounts of the active lipid
  • DOPE ethanolamine
  • Plasmid pCMV a-gal which contains the
  • E. Coli a-galactosidase (gene) under the control of the powerful cytomegalovirus promoter
  • Example 20 Transfection of HepG2 and HeLa cells.
  • liposome in water were diluted in polystyrene tubes containing lOO ⁇ l of serum-free, antibiotic-free RPMI-1640 and to these tubes were added 150 ng of plasmid in lOO ⁇ l of the
  • Keratinocytes Cells were grown in serum free medium (SFM) and plated on 35 mm plates (6 wells) such that the confluence after 24h was above 50%. Plasmid reporter (2 ⁇ g and 5 ⁇ g,
  • the cells were transfected during 4h and 6h, respectively.
  • the DNA/liposome complex was removed by rinsing with SFM and the cells incubated for 48h under normal growth conditions and then assayed for the appropiate marker.
  • Example 22 Transfection and CAT assay of Turkat Cells (suspension cells).
  • the cell suspension culture was transferred to a 50 ml conical tube and centrifuged at
  • the plasmid and lipid solution were dissolved in 110 ⁇ l of serum-free medium and a separately in another tube were diluted 30 ⁇ l of the lipid solution in 70 ⁇ l of serum-free medium.
  • the plasmid and lipid solution were diluted 30 ⁇ l of the lipid solution in 70 ⁇ l of serum-free medium.
  • Example 23 Assay for transient transfection (adherent cells).
  • the cells were washed twice with Dulbecco's PBS and stained with freshly prepared
  • the cells were stained with 0.5 ml of ⁇ -galactosidase histochemical stain (0.1% x-gal, 5mM potassium ferrocyanide, 5mM potassium ferrocyanide, 2mM MgCl 2 in PBS)
  • HeLaS3 human cervical carcinoma
  • keratinocytes cells Primary cells are cells that are freshly isolated from humans or animals and which, unlike the cultured cell lines, reflect the potential behavior of a compound in vivo
  • Table IN shows the relative efficiency of compounds 6d and 13d versus DOTMA (LipofectinTM
  • these compounds show a relative range of activities of 5.3 to 6.0 times higher than that of the Lipofectin control. At the same time their cell toxicity was below 5%, unlike the control which showed toxicity in the 10-20% range. Thus, these lipid reagents are superior to the
  • Table V depicts the percentages of ⁇ -gal positive cells (absolute number) which were obtained in primary human epidermal keratinocytes with compounds 5a and 6d versus
  • DOSPA control LipofectamineTM Reagent, Life Technologies, Inc. supra
  • keratinocytes are also a potential target cells for genetic therapy (Fenjves, E.S. et al., Hum
  • Cells were plated in 48 well plates at a density of 1 x 10 per well in 0.5 ml of growth medium. After 24h, the cells were washed with serum free medium and transfected with a suboptimal amount (150 ng) of plasmid pCMV- ⁇ gal. using 1,3 and 5 ⁇ l (1,3 and 5 ⁇ g) of lipid formulation. The amount giving the highest level of transfection efficiency is shown. The experiment was run in triplicate.
  • Cells were plated in 48 well plates at a density of 1 x 10 5 per well in 0.5 ml of growth medium. After 24h, the cells were washed with serum free medium and transfected with a suboptimal amount (150 ng) of plasmid pCMV- ⁇ gal. using 1,3 and 5 ⁇ l (1,3 and 5 ⁇ g) of lipid formulation. The amount giving the highest level of transfection efficiency is shown. The experiment was run in triplicate.
  • Lipid/DOPE molar ratio
  • Optimal Liposome Amount CAT Activity (mU/well) W
  • 35 mm plates were inoculated with cell isolates and transfected at 90% confluence. 2 ⁇ g of firefly luciferase plasmid were mixed with 12 ⁇ g of the lipids and then added to the cells. After 5h, the transfection was quenched by removal of the DNA/Lipid complex and the cells incubated for 72h. Cells were lysated and aliquats assayed for luciferase activity. Cell toxicity, determined by the trypan blue method, was below 5% for lipids 6d and 13d and between 10-20% for Lipofectin.
  • Lipid/DOPE (molar ratio) Optimal Liposome Amount ⁇ -Gal Positive Cells (%) (fig)
  • Cells were seeded at 2xl0 5 /well in 35 mm wells and transfected the next day. 5 ⁇ g of ⁇ gal DNA were mixed with the appropiate amount of lipids and added to the cells. After 4h, the medium was replaced and the cells incubated for additional 48h and then assayed. Blue cells were observed under the microscope and counted.
  • lipids have a polyether backbone which generally
  • polyether functionality which is also present in
  • polyethylene glycol PEG
  • PEG polyethylene glycol
  • N,N -dipalmityl-triethyleneglycoldiamine (240mg, 0.4mmol) was dissolved in an
  • DOPE colipid dioleoylphosphatidylethanolamine
  • Lipid/DOPE (molar ratio) Liposome Amount ( ⁇ g) ⁇ -Gal Positive Cells (%)
  • Cells were plated in 35 mm well plates at a density of 1 x 10 per well in 1 ml of growth medium. After 24 h (ca 70% confluence), the cells were washed with serum free medium and transfected with 2 ⁇ of plasmid pCMV- ⁇ gal. Cells were assayed 48 h after transfection for the ⁇ gal gene protein.
  • Lipid/DOPE (molar ratio) DNA/Liposomes ⁇ Gal Positive Cells (%)
  • Cells were transfected with the plasmid pCMV- ⁇ gal in 35 mm well plates at 80% confluence in 1 ml of growth medium. After 24 h, the cells were assayed for the expression of the ⁇ gal gene protein.
  • COS1 cells and CHO cells following essentially the same procedures described in
  • lipids having a glyceryl backbone are provided.
  • These glyceryl backbone based lipids have a dicationic bicyclic triethylene
  • DOTMA Lipofectin reagentTM, Life Technologies, Inc.
  • Scheme V of Figure 5 shows the general synthesis of glyceryl backbone
  • This material was formulated with a colipid dioleoyl phosphatidyl ethanolamine (DOPE) at a 1:1.5., Lipid:DOPE, respectively.
  • DOPE colipid dioleoyl phosphatidyl ethanolamine
  • compound 26 is produced by acylating the starting diol with palmitoyl chloride in the presence of triethylamine to
  • the diester in a 59% yield.
  • the diester is treated with an excess of the highly nucleophilic triethylene diamine (Dabco ® ) which gives the desired lipid (compound 27) in
  • ethers are made by using alkyl iodides (e.g. methyl iodide or activated esters (e.g. tosylates or triflates) instead of the acyl halides
  • Liposomes containing lipids produced in accordance with the present invention Liposomes containing lipids produced in accordance with the present invention and
  • Table VIII shows remarkable transfection efficiencies for liposomes derived from compounds (6d) and (24). Especially, compound (6d) has proven to be an outstanding
  • liposome reagents of the previous art were considered superior if transfection efficiencies

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Dispersion Chemistry (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

La présente invention concerne des lipides cationiques utilisés pour transfecter des macromolécules, ces lipides présentant un polyéther ou un squelette glycérique. En outre, ces lipides peuvent être contenus dans un liposome pour transfecter efficacement des types variés de cellules et améliorer l'efficacité de la transfection. Par ailleurs, cette invention concerne des compositions renfermant lesdits lipides ainsi que leurs procédés d'utilisation.
PCT/US1999/019629 1998-08-27 1999-08-27 Nouveaux lipides cationiques Ceased WO2000012454A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU55881/99A AU5588199A (en) 1998-08-27 1999-08-27 Novel polycationic lipids

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US9807398P 1998-08-27 1998-08-27
US60/098,073 1998-08-27

Publications (2)

Publication Number Publication Date
WO2000012454A1 true WO2000012454A1 (fr) 2000-03-09
WO2000012454A9 WO2000012454A9 (fr) 2000-06-15

Family

ID=22266831

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1999/019629 Ceased WO2000012454A1 (fr) 1998-08-27 1999-08-27 Nouveaux lipides cationiques

Country Status (2)

Country Link
AU (1) AU5588199A (fr)
WO (1) WO2000012454A1 (fr)

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006060246A2 (fr) 2004-11-22 2006-06-08 Dharmacon, Inc. Appareil et systeme contenant des compositions de silençage genique de controle seches
EP1386455B1 (fr) * 2001-03-30 2011-12-21 Intel Corporation Procede et appareil de realisation d'acheminement dans un reseau
CN103739510A (zh) * 2014-01-16 2014-04-23 中国科学院化学研究所 含氨基末端及双胺基的表面活性剂的制备方法及分离方法
JP2018035121A (ja) * 2016-09-02 2018-03-08 東ソー株式会社 カチオン性ジェミニ型界面活性剤
US10195280B2 (en) 2014-07-15 2019-02-05 Life Technologies Corporation Compositions and methods for efficient delivery of molecules to cells
WO2019176079A1 (fr) * 2018-03-16 2019-09-19 株式会社 東芝 Composé biodégradable, particule lipidique, composition contenant des particules lipidiques et kit
CN110256287A (zh) * 2019-05-08 2019-09-20 山东汉鸿新材料科技有限公司 高含量n-脂肪烷基-1，3-丙撑二胺的合成方法
US10501404B1 (en) 2019-07-30 2019-12-10 Factor Bioscience Inc. Cationic lipids and transfection methods
US12344572B2 (en) 2019-07-03 2025-07-01 Factor Bioscience Inc. Cationic lipids and transfection methods

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE383331T1 (de) 1998-11-12 2008-01-15 Invitrogen Corp Transportreagentien
KR101147147B1 (ko) 2004-04-01 2012-05-25 머크 샤프 앤드 돔 코포레이션 Ｒｎａ 간섭의 오프 타겟 효과 감소를 위한 변형된폴리뉴클레오타이드

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4897355A (en) * 1985-01-07 1990-01-30 Syntex (U.S.A.) Inc. N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US5171678A (en) * 1989-04-17 1992-12-15 Centre National De La Recherche Scientifique Lipopolyamines, their preparation and their use
US5334761A (en) * 1992-08-28 1994-08-02 Life Technologies, Inc. Cationic lipids

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4897355A (en) * 1985-01-07 1990-01-30 Syntex (U.S.A.) Inc. N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US5171678A (en) * 1989-04-17 1992-12-15 Centre National De La Recherche Scientifique Lipopolyamines, their preparation and their use
US5334761A (en) * 1992-08-28 1994-08-02 Life Technologies, Inc. Cationic lipids

Cited By (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1386455B1 (fr) * 2001-03-30 2011-12-21 Intel Corporation Procede et appareil de realisation d'acheminement dans un reseau
WO2006060246A2 (fr) 2004-11-22 2006-06-08 Dharmacon, Inc. Appareil et systeme contenant des compositions de silençage genique de controle seches
CN103739510A (zh) * 2014-01-16 2014-04-23 中国科学院化学研究所 含氨基末端及双胺基的表面活性剂的制备方法及分离方法
CN103739510B (zh) * 2014-01-16 2015-11-18 中国科学院化学研究所 含氨基末端及双胺基的表面活性剂的制备方法及分离方法
US11872285B2 (en) 2014-07-15 2024-01-16 Life Technologies Corporation Compositions and methods for efficient delivery of molecules to cells
US10195280B2 (en) 2014-07-15 2019-02-05 Life Technologies Corporation Compositions and methods for efficient delivery of molecules to cells
US10792362B2 (en) 2014-07-15 2020-10-06 Life Technologies Corporation Compositions and methods for efficient delivery of molecules to cells
JP2018035121A (ja) * 2016-09-02 2018-03-08 東ソー株式会社 カチオン性ジェミニ型界面活性剤
WO2019176079A1 (fr) * 2018-03-16 2019-09-19 株式会社 東芝 Composé biodégradable, particule lipidique, composition contenant des particules lipidiques et kit
US10945956B2 (en) 2018-03-16 2021-03-16 Kabushiki Kaisha Toshiba Biodegradable compound, lipid particles, composition and kit comprising lipid particles
JPWO2019176079A1 (ja) * 2018-03-16 2020-04-16 株式会社東芝 生分解性化合物、脂質粒子、脂質粒子を含む組成物、およびキット
CN110256287A (zh) * 2019-05-08 2019-09-20 山东汉鸿新材料科技有限公司 高含量n-脂肪烷基-1，3-丙撑二胺的合成方法
CN110256287B (zh) * 2019-05-08 2023-03-10 山东汉鸿新材料科技有限公司 高含量n-脂肪烷基-1，3-丙撑二胺的合成方法
US12344572B2 (en) 2019-07-03 2025-07-01 Factor Bioscience Inc. Cationic lipids and transfection methods
US10611722B1 (en) 2019-07-30 2020-04-07 Factor Bioscience Inc. Cationic lipids and transfection methods
US11242311B2 (en) 2019-07-30 2022-02-08 Factor Bioscience Inc. Cationic lipids and transfection methods
US10752576B1 (en) 2019-07-30 2020-08-25 Factor Bioscience Inc. Cationic lipids and transfection methods
US11814333B2 (en) 2019-07-30 2023-11-14 Factor Bioscience Inc. Cationic lipids and transfection methods
US10556855B1 (en) 2019-07-30 2020-02-11 Factor Bioscience Inc. Cationic lipids and transfection methods
US10501404B1 (en) 2019-07-30 2019-12-10 Factor Bioscience Inc. Cationic lipids and transfection methods
US12384740B2 (en) 2019-07-30 2025-08-12 Factor Bioscience Inc. Cationic lipids and transfection methods

Also Published As

Publication number Publication date
AU5588199A (en) 2000-03-21
WO2000012454A9 (fr) 2000-06-15

Similar Documents

Publication Publication Date Title
EP0741689B1 (fr) Lipides d'ammonium, de sulfonium et de phosphonium polycationiques tres concentres
Niculescu-Duvaz et al. Structure-activity relationship in cationic lipid mediated gene transfection
CA2237316C (fr) Lipides cationiques complexes
EP4352038A2 (fr) Lipides cationiques ionisables d'administration d'arn
US6638529B2 (en) Amide-based cationic lipids
AU731503B2 (en) Cationic amphiphile compositions for intracellular delivery of therapeutic molecules
WO2000030444A1 (fr) Liposomes cationiques pour transfert genique
EP1328254A2 (fr) Formulations de lipides pour une administration ciblee
WO1997013743A1 (fr) Cytofectines cationiques polyfonctionnelles, formulations et procedes pour generer des complexes de transfection actifs cytofectines/polynucleotides
WO1996018372A2 (fr) Amphiphiles cationiques et plasmides destines a la liberation intracellulaire de molecules therapeutiques
WO1998002190A2 (fr) Complexes adn/amphiphiles cationiques
JP2014208687A (ja) トランスフェクションエンハンサー要素を含む脂質および脂質集合体
WO1998043994A1 (fr) Amphiphiles cationiques pour administration intracellulaire de molecules a vocation therapeutique
WO1997042819A9 (fr) Lipides cationiques destines a la transfection de molecules neutres ou chargees negativement a l'interieur de cellules vivantes
WO1997042819A1 (fr) Lipides cationiques destines a la transfection de molecules neutres ou chargees negativement a l'interieur de cellules vivantes
WO2000012454A1 (fr) Nouveaux lipides cationiques
US6281371B1 (en) Lipopolyamines, and the preparation and use thereof
WO1998050418A1 (fr) Amphiphiles cationiques contenant des lieurs obtenus a partir d'acides amines neutres ou charges positivement
AU8113398A (en) Novel lipid complexes for transferring at least one therapeutically active substance, in particular a polynucleotide, into a target cell, and use in gene therapy
US20240300891A1 (en) Ionizable lipids, lipid nanoparticles for mrna delivery and methods of making the same
EP1019361A1 (fr) Cytofectines cationiques polyfonctionnelles, formulations et procede de generation de complexes actifs de transfection cytofectine:polynucleotide
CA3226487A1 (fr) Lipides ionisables, nanoparticules lipidiques pour l'administration d'arnm et leurs procedes de fabrication
WO2025194409A1 (fr) Composés lipidiques cationiques ionisables pour système d'administration et leurs utilisations
WO1998050416A1 (fr) Amphiphiles cationiques a groupes lipophiles steroides multiples
US20250162981A1 (en) Ionizable lipidoid compositions and therapeutic uses thereof

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: C2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: C2

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

COP Corrected version of pamphlet

Free format text: PAGES 37 AND 38, CLAIMS, REPLACED BY NEW PAGES 37 AND 38; PAGES 1/16-16/16, DRAWINGS, REPLACED BY NEW PAGES 1/16-16/16; DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase